Literature DB >> 6627205

Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases.

C Capella, J M Polak, R Buffa, F J Tapia, P Heitz, L Usellini, S R Bloom, E Solcia.   

Abstract

Thirty-two tumors (31 pancreatic and one jejunal) all associated with severe watery diarrhea, increased VIP levels in blood and most with hypokalemia, were investigated. The VIP content of tumor tissue ranged from 23 to 15,000 pmol/g. VIP immunoreactive cells were detected histochemically in 24 of 28 tumors investigated, PP immunoreactive cells in 11 of 28 tumors, hCG (alpha chain) immunoreactive cells in 12 of 25 tumors, and neuron specific enolase (NSE) immunoreactive cells in 24 of 26 tumors (the 2 negative results were due to inadequate fixation). All cases showed light microscopic features of epithelial endocrine tumors. Electron microscopy demonstrated a prevalence of agranular, poorly granulated and a minority of well granulated cells. Most secretory granules were round, small (150+/- 30 nm diameter) and of moderate electron density, resembling those of the so-called D1 cells. By electron immunocytochemistry, PP was directly localized in a subpopulation of relatively larger granules (154 +/- 22 nm core diameter) showing closely applied membranes. VIP-storing granules, directly identified only in the jejunal tumor, appear to correspond to a subpopulation of slightly smaller P-type granules (126 +/- 37 nm core diameter) showing a narrow, clear halo. The origin, behavior, and diagnostic criteria of VIPomas are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627205     DOI: 10.1002/1097-0142(19831115)52:10<1860::aid-cncr2820521017>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  [Tumors of the endocrine pancreas].

Authors:  M Anlauf; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

Review 2.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Histopathology, hormone products, and clinicopathological profile of endocrine tumors of the upper small intestine: A study of 44 cases.

Authors:  Carlo Capella; Cristina Riva; Guido Rindi; Fausto Sessa; Luciana Usellini; Annamaria Chiaravalli; Luciano Carnevali; Enrico Solcia
Journal:  Endocr Pathol       Date:  1991-06       Impact factor: 3.943

4.  Pancreatic endocrine tumours associated with WDHA syndrome. An immunohistochemical and electron microscopic study.

Authors:  A Ooi; T Kameya; M Tsumuraya; K Yamaguchi; K Abe; Y Shimosato; N Yanaihara
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

5.  Pancreatic polypeptide (PP) cells in the PP-rich lobe of the human pancreas are identified ultrastructurally and immunocytochemically as F cells.

Authors:  R Fiocca; F Sessa; P Tenti; L Usellini; C Capella; M M O'Hare; E Solcia
Journal:  Histochemistry       Date:  1983

Review 6.  [Tumors of the endocrine pancreas].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

7.  Well-differentiated endocrine tumours of the middle ear and of the hindgut have immunocytochemical and ultrastructural features in common.

Authors:  C Azzoni; M Bonato; T D'Adda; L Usellini; F Piazza; A Gandolfi; C Bordi; C Capella
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.

Authors:  Shoko Nakayama; Taiji Yokote; Kichinosuke Kobayashi; Yuji Hirata; Tetsuya Hiraiwa; Izumi Komoto; Kazuho Miyakoshi; Yoshiko Yamakawa; Takayuki Takubo; Motomu Tsuji; Masayuki Imamura; Toshiaki Hanafusa
Journal:  Endocrine       Date:  2009-01-30       Impact factor: 3.633

Review 9.  Pancreatic vipomas: spectrum of presentation and evolution of diagnostic and therapeutic modalities.

Authors:  S F Leavey; H Holloway; M G Courtney; B E Lane; D Royston; K D Buchanan; J F Fielding
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

Review 10.  [Drug therapy of endocrine neoplasms. Part II: Malignant gastrinomas, insulinomas, glucagonomas, carcinoids and other tumors].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.